1. Report Overview

1.1 Why You Should Read This Report

1.2 How This Report Delivers

1.3 Key Questions Answered by This Analytical Report Include:

1.4 Who is This Report For?

1.5 Methodology

1.5.1 Primary Research

1.5.2 Secondary Research

1.5.3 Market Evaluation & Forecasting Methodology

1.6 Frequently Asked Questions (FAQ)

1.7 Associated Visiongain Reports

1.8 About Visiongain

2. Introduction to the Idiopathic Pulmonary Fibrosis (IPF)

2.1 What is IPF?

2.2 Aetiology – Causes and Risk Factors

2.3 Symptoms

2.4 Stages of IPF

2.5 Diagnosis

2.5.1 Diagnostic Tests

2.5.2 Pulmonary Function Testing/Lung Function Testing

2.5.3 Oximetry

2.5.4 Lung Biopsy

2.5.5 Chest X-ray

2.5.6 Computerized Tomography (CT)

2.5.7 Echocardiogram

2.6 Epidemiology

2.6.1 Methodology

2.6.2 Epidemiology by Country

2.6.3 Epidemiology by Disease Severity

2.6.4 Epidemiology by Gender

2.6.5 Historical Prevalence in Major Markets

2.6.1 Forecast of IPF in Major Markets: 2019-2029

2.6.1.1 The U.S.

2.6.1.2 France

2.6.1.3 Germany

2.6.1.4 The United Kingdom

2.6.1.5 Italy

2.6.1.6 Spain

2.6.1.7 Japan

2.7 Humanistic and Economic Burden

2.7.1 Co-morbidities

2.7.2 Mortality

2.7.3 Healthcare Utilization & Economic Burden

2.8 Prevention and Treatment

2.8.1 Guidelines

2.8.2 Non-pharmacologic Management

2.8.2.1 Quit Smoking

2.8.2.2 Oxygen therapy

2.8.2.3 Pulmonary Rehabilitation

2.8.2.4 Vaccination

2.8.2.5 Maintain Healthy Weight

2.8.2.6 Lung Transplantation

2.8.3 Pharmacologic Treatments

3. Introduction to the Global Anti- Anti-Idiopathic Pulmonary Fibrosis Drugs Market

3.1 Market Structure

3.2 Market Definition and Scope

3.3 Classification by Mechanism of Action

3.3.1 Anti-fibrotics

3.3.2 Tyrosine Kinase Inhibitors

3.3.3 Anti-inflammatory Drugs

3.3.4 Immunosuppressant

3.3.5 Other Mechanisms

3.4 Classification by Innovator or Off-label Drugs

3.4.1 Innovator Drugs

3.4.2 Off-label Drugs

4. Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2029

4.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2018

4.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2019-2029

4.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action

4.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Mechanism of Action: Forecast 2019-2029

4.4.1 Global Anti-fibrotics Drugs Market Forecast, 2019-2029

4.4.2 Global Tyrosine Kinase Inhibitors Drugs Market Forecast, 2019-2029

4.4.3 Global Anti-inflammatory Drugs Market Forecast, 2019-2029

4.4.4 Global Immunosuppressant Drugs Market Forecast, 2019-2029

4.4.5 Other MoA Drugs Market Forecast, 2019-2029

4.4.6 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Mechanism of Action: Share Forecast 2019-2029

4.5 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label Drugs, 2018

4.5.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label drugs: Forecast 2019-2029

4.5.1.1 Global Innovator Drugs Market Forecast, 2019-2029

4.5.1.2 Global Off-label Drugs Market Forecast, 2019-2029

4.5.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Generics: Share Forecast 2019-2029

4.6 Overall Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Drivers, Restraints and Trends

5. Leading Anti-Idiopathic Pulmonary Fibrosis Drugs

5.1 Snapshot of Anti-Idiopathic Pulmonary Fibrosis Drugs Sales, Historical Sales, & Forecast 2019-2029

5.1.1 Esbriet

5.1.1.1 Esbriet: Drug Profile

5.1.1.2 Esbriet: Historical Sales

5.1.1.3 Esbriet Sales Forecast 2019-2029

5.1.1.4 Esbriet Sales by Geography, 2018

5.1.2 Ofev

5.1.2.1 Ofev: Drug Profile

5.1.2.2 Ofev: Historical Sales

5.1.2.3 Ofev: Forecast 2019-2029

5.1.2.4 Ofev: Sales by Geography, 2016

5.2 Off-label Drugs

6. Leading National Markets Forecast to 2029

6.1 Geographical Breakdown of Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2018

6.2 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region, 2019-2029

6.3 The U.S. Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2018

6.3.1 The U.S. Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029

6.4 EU5 Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2018

6.4.1 EU5 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029

6.4.1.1 Germany Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029

6.4.1.2 U.K. Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029

6.4.1.3 France Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029

6.4.1.4 Spain Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029

6.4.1.5 Italy Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029

6.5 Japan Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029

6.6 RoW Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029

7. Research and Development for Treating IPF

7.1 Novel Mechanism of Action of Pipeline Drugs

7.2 Active Pipeline Molecules

7.3 Promising Potential Pipeline Molecules

7.3.1 Phase III Molecules

7.3.1.1 Recomodulin (ART-123)

7.3.2 Phase II Molecule

7.3.2.1 Pamrevlumab (FG-3019)

7.3.2.2 PRM-151

7.3.2.3 Erivedge (Vismodegib)

7.3.2.4 Opsumit (Macitentan)

7.3.2.5 INOpulse

7.3.2.6 GBT-440

7.3.2.7 TipelU.K.ast (MN-001)

7.3.2.8 TD-139

7.3.2.9 BG00011 (STX-100)

7.3.2.10 LT-1001 & LT-1002

7.3.2.11 KD-025 (SLx-2119)

7.3.2.12 SAR 156597

7.3.2.13 PBI4050

7.3.2.14 MK-7264(AF 219)

7.3.2.15 Lebrikizumab

7.3.2.16 GLPG-1690

7.3.3 Phase I trial

7.3.3.1 PXS 4728A

7.3.3.2 PTL 202

7.3.3.3 GSK3008348

7.3.3.4 Omipalisib (GSK-2126458)

7.3.3.5 MMI-0100

7.3.3.6 Deupirfenidone(SD 560)

7.3.3.7 ZL 2012

8. Pricing and Reimbursement Overview

8.1 Ofev

8.1.1 NICE (U.K.)

8.1.2 SMC (Scotland)

8.1.3 PBAC (Australia)

8.1.4 CADTH (Canada)

8.1.5 G-BA (Germany)

8.1.6 HAS (France)

8.1.7 Overall HTA Challenges

8.2 Esbriet

8.2.1 NICE (U.K.)

8.2.2 SMC (Scotland)

8.2.3 G-BA (Germany)

8.2.4 HAS (France)

8.2.5 CADTH (Canada)

9. Qualitative Analysis of the Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market

9.1 SWOT Analysis



10. Leading Companies in the Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2018

10.1 Roche

10.1.1 Company Profiles

10.1.2 Roche Holding AG

10.1.3 Roche Holding AG: Product Portfolio

10.1.4 Recent Developments

10.2 Boehringer Ingelheim GmbH

10.2.1 Boehringer Ingelheim: Product Portfolio

10.2.2 Recent Developments

10.3 Shionogi & Co. Ltd.

10.3.1 Shionogi & Co. Ltd.: Product Portfolio

10.3.2 Recent Developments

10.4 Merck & Co.

10.4.1 Recent Developments

10.5 Cipla Limited

10.5.1 Cipla Limited: Product Portfolio

10.5.2 Recent Developments

10.6 Galapagos NV

10.6.1 Galapagos NV: Product Portfolio

10.7 MediciNova Inc.

10.7.1 MediciNova Inc.: Product Portfolio

11. Conclusions

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Table

Table 2.1: GAP Index for IPF

Table 2.2: GAP Staging for IPF

Table 2.3: Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016 (absolute cases)

Table 2.4: Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis by Severity, ages 40+, 2016 (absolute cases)

Table 2.5 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the U.S., ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029

Table 2.6 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the U.S., ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029

Table 2.7 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in France, ages 40: absolute cases, AGR (%), CAGR (%), 2019-2029

Table 2.8 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Germany, ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029

Table 2.9 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the U.K., ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029

Table 2.10 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Italy, ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029

Table 2.11 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Spain, ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029

Table 2.12 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Japan, ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029

Table 3.1: Anti-fibrotic molecular targets and pharmacologic agents

Table 3.2 Mechanism of Action of Innovator Drugs for the treatment of IPF

Table 4.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Markets by Segmentation: Revenue ($m), and Market Share (%), 2018

Table 4.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2019-2029: Revenue ($m), AGR (%), CAGR (%)

Table 4.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action 2019-2029: Revenue ($m), AGR (%), CAGR (%)

Table 4.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: AGR (%), 2019-2029

Table 4.5 Global Ant fibrotic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.6 Global Tyrosine Kinase Inhibitor Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.7 Global Anti-inflammatory Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.8 Global Immunosuppressant Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.9 Global Other MoA Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.10 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market

Forecast by Mechanism of Action: Market Share (%), 2019-2029

Table 4.11 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator and Off-label Drugs: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.12 Global Anti-Idiopathic Pulmonary Fibrosis Innovator Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.13 Global Anti-Idiopathic Pulmonary Fibrosis Off-label Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.14 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Generics: Market Share (%), 2019-2029

Table 5.1 Branded Anti-Idiopathic Pulmonary Fibrosis Drugs

Table 5.2 Leading Anti-Idiopathic Pulmonary Fibrosis Drug Sales, Revenue ($m), Market Share (%), 2018

Table 5.3 Esbriet: Drug Profile

Table 5.4 Esbriet Sales Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 5.5 Ofev: Drug Profile

Table 5.6 Ofev Sales Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 6.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Revenue ($m), and Market Share (%), 2018

Table 6.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 6.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: AGR (%), 2019-2029

Table 6.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Market Share (%), 2019-2029

Table 6.5 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the U.S. 2019-2029: Revenue ($m), AGR (%), CAGR (%)

Table 6.6 Anti-Idiopathic Pulmonary Fibrosis Drugs in the EU5 region: Revenue ($m), Global Market Share (%), EU5 Market Share (%), 2018

Table 6.7 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in EU5 Region: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 6.8 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: Market Share (%), 2019-2029

Table 6.9 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: AGR (%), 2019-2029

Table 6.10 Germany Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 6.11 The U.K. Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 6.12 France Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 6.13 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 6.14 Italy Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 6.15 Japan nti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 6.16 RoW Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 7.1: Active Pipeline Molecules under Development for Treating IPF

Table 7.2: Pamrevlumab - Completed and Ongoing Clinical Trials

Table 8.1 Ofev: HTA Agencies’ Decision Outcomes

Table 8.2 Esbriet: HTA Agencies’ Decision Outcomes

Table 10.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Market Share (%), 2018

Table 10.2 Roche Holding AG: Overview, 2018

Table 10.3 Anti-Idiopathic Pulmonary Fibrosis Drug Offerings

Table 10.4 Boehringer Ingelheim: Overview, 2018

Table 10.5 Anti-Idiopathic Pulmonary Fibrosis Drug Offerings

Table 10.6 Shionogi Seiyaku: Overview, 2018

Table 10.7 Anti-Idiopathic Pulmonary Fibrosis Drug Offerings

Table 10.8 Merck & Co.: Overview, 2018

Table 10.9 Cipla Limited: Overview, 2018

Table 10.10 Anti-Idiopathic Pulmonary Fibrosis Drug Offerings

Table 10.11 Galapagos NV: Overview, 2018

Table 10.12 Anti-Idiopathic Pulmonary Fibrosis Drug Offerings

Table 10.13 MediciNova Inc.: Overview, 2018

Table 10.14 Anti-Idiopathic Pulmonary Fibrosis Drug Offerings

List of Figure

Figure 1.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation Overview

Figure 2.1: Types of Idiopathic Interstitial Pneumonias

Figure 2.2: Pathogenesis of Idiopathic Pulmonary Fibrosis

Figure 2.3 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016 (absolute cases)

Figure 2.4 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016 (%)

Figure 2.5 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis by Severity, ages 40+, 2016 (%)

Figure 2.6 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis by Gender in G7 Markets, ages 40+, 2016 (%)

Figure 2.7 Historical Prevalence of IPF in G7 Markets, absolute cases; 2010-2015

Figure 2.8 Historical Prevalence of IPF in G7 Markets, CAGR, 2010-2015

Figure 2.9 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the U.S., ages 40+: absolute cases, AGR (%), 2019-2029

Figure 2.10 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in France, ages 40+: absolute cases, AGR (%), 2019-2029

Figure 2.11 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Germany, ages 40+: absolute cases, AGR (%), 2019-2029

Figure 2.12 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the U.K., ages 40+: absolute cases, AGR (%), 2019-2029

Figure 2.13 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Italy, ages 40+: absolute cases, AGR (%), 2019-2029

Figure 2.14 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Spain, ages 40+: absolute cases, AGR (%), 2019-2029

Figure 2.15 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Japan, ages 40+: absolute cases, AGR (%), 2019-2029

Figure 2.16: Comparison of Recommendations in the 2015 and 2011 Idiopathic Pulmonary Fibrosis Guidelines

Figure 3.1 Anti-Idiopathic Pulmonary Fibrosis Drugs Classification by Mechanism of Action, 2018

Figure 3.2: Inflammatory Pathway in IPF

Figure 4.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2019-2029: Revenue ($m), AGR (%)

Figure 4.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action 2018, Revenue ($m)

Figure 4.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action: Market Share (%), 2018

Figure 4.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action 2019-2029: Revenue ($m), AGR (%)

Figure 4.5 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action 2018 and 2029: Revenue ($m), CAGR (%), 2018 and 2018

Figure 4.6 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: AGR (%), 2019-2029

Figure 4.7 Global Ant fibrotic Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.8 Global Tyrosine Kinase Inhibitor Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.9 Global Anti-inflammatory Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.10 Global Immunosuppressant Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.11 Global Other MoA Drugs Market: Revenue ($m), AGR (%), 2019-2029

Figure 4.12 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: Market Share (%), 2019-2029

Figure 4.13 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action: Market Share Forecast (%), 2018

Figure 4.14 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action: Market Share (%), 2029

Figure 4.15 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Innovator and Off-label Drugs: Revenue ($m), 2018

Figure 4.16 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Innovator and Off-label Drugs: Market Share (%), 2018

Figure 4.17 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Off-label drugs: Revenue ($m), Global AGR (%), 2019-2029

Figure 4.18 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator and Off-label Drugs: Revenue 2018 and 2029 ($m), CAGR 2019-2029 (%)

Figure 4.19 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator and Off-label Drugs: AGR (%), 2019-2029

Figure 4.20 Global Anti-Idiopathic Pulmonary Fibrosis Innovator Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.21 Global Anti-Idiopathic Pulmonary Fibrosis Off-label Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.22 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Generics: Market Share (%), 2019-2029

Figure 4.23 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label Drugs: Market Share (%), 2018

Figure 4.24 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label Drugs: Market Share (%), 2029

Figure 4.25 Trends in Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016

Figure 4.26 Trends in Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2018

Figure 5.1 Leading Anti-Idiopathic Pulmonary Fibrosis Drugs Sales, Revenue ($m), 2018

Figure 5.2 Leading Anti-Idiopathic Pulmonary Fibrosis Drug Sales, Market Share (%), 2018

Figure 5.3 Anti-Idiopathic Pulmonary Fibrosis Sales Forecast, Market Share (%), 2029

Figure 5.4 Global Anti-Idiopathic Pulmonary Fibrosis Sales Forecast, Ofev and Esbriet, Revenue ($m), 2019-2029

Figure 5.5 Leading Anti-Idiopathic Pulmonary Fibrosis Drugs, Historical Sales, Revenue ($m), 2011-2016

Figure 5.6 Anti-Idiopathic Pulmonary Fibrosis Drugs, Historical Sales Trend, Revenue ($m), 2011-2016

Figure 5.7 Esbriet Global Sales: Revenue ($million), 2011-2016

Figure 5.8 Global Anti-Idiopathic Pulmonary Fibrosis Off-label Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 5.9 Esbriet Sales Forecast 2019-2029: Revenue ($million), AGR (%)

Figure 5.10 Esbriet Sales by Geography: Revenue ($m), 2018

Figure 5.11 Esbriet Sales by Geography: Market Share (%), 2018

Figure 5.12 Ofev Global Sales: Revenue ($m), 2014-2016

Figure 5.13 Global Anti-Idiopathic Pulmonary Fibrosis Off-label Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 5.14 Ofev Sales Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 5.15 Ofev Sales by Geography: Revenue ($m), 2018

Figure 5.16 Ofev Sales by Geography: Market Share (%), 2018

Figure 5.17 Global Anti-Idiopathic Pulmonary Fibrosis Off-label drugs Market: Market Share by Individual Compound (%), 2018

Figure 6.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Region/Country

Figure 6.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Revenue ($m), 2018

Figure 6.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Market Share 2018 (%)

Figure 6.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Revenue ($m), AGR (%), 2019-2029

Figure 6.5 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region 2018, 2024, 2029: Revenue ($m), CAGR 2019-2029 (%)

Source: Visiongain 2019

Figure 6.6 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: AGR (%), 2019-2029

Figure 6.7 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Market Share (%), 2019-2029

Figure 6.8 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Market Share Forecast 2018 (%)

Figure 6.9 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Market Share Forecast 2024 (%)

Figure 6.10 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Market Share Forecast 2029 (%)

Figure 6.11 Anti-Idiopathic Pulmonary Fibrosis Drugs Market in the U.S.: 2018 Revenue ($m), Market Share %

Figure 6.12 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the U.S. 2019-2029: Revenue ($m), AGR (%)

Figure 6.13 Anti-Idiopathic Pulmonary Fibrosis Drugs Market in the EU5: Global Market Share (%), 2018

Figure 6.14 Anti-Idiopathic Pulmonary Fibrosis Drugs Market in the EU5 Countries: Market Share (%), 2018

Figure 6.15 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the EU5 Countries: Revenue ($m), EU5 AGR (%), 2019-2029

Figure 6.16 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the EU5 Countries 2018 and 2029: Revenue ($m), CAGR 2019-2029 (%)

Figure 6.17 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: Market Share (%), 2019-2029

Figure 6.18 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: AGR (%), 2019-2029

Figure 6.19 Germany Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 6.20 The U.K. Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 6.21 France Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 6.22 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in Spain: Revenue ($m), AGR (%), 2019-2029

Figure 6.23 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in Italy: Revenue ($m), AGR (%), 2019-2029

Figure 6.24 Japan Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 6.25 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in RoW: Revenue ($m), AGR (%),2019-2029

Figure 7.1 Anti-Idiopathic Pulmonary Fibrosis Clinical Pipeline Segmentation by Phase, 2018

Figure 7.2 Key Molecular Targets of Idiopathic Pulmonary Fibrosis

Figure 7.3 Recomodulin – Mechanism of Action

Figure 9.1 SWOT Analysis of the Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016

Figure 10.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Revenue ($m), 2018

Figure 10.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Market Share (%), 2018

Figure 10.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Revenue ($m) 2016

Figure 11.1 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016 (%)

Figure 11.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2019-2029: Revenue ($m), AGR (%)